Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 6,741–6,760 of 17,964 drug recalls

Drug Recall Ongoing Historical recordClass II

Regular Strength Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219. NDC 67751-151-01.

by Sanofi-Aventis U.S. LLC

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Recall initiated
October 22, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Maximum Strength Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219. NDC's: 0597-0121-01, 0597-0121-06, 0597-0121-08, 0597-0121-09, 0597-0121-11, 0597-0121-24, 0597-0121-38, 0597-0121-50, 0597-0121-64, 0597-0121-66, 0597-0121-68, 0597-0121-78, 0597-0121-80, 0597-0121-82, 0597-0121-85, 0597-0121-90, 0597-0121-94.

by Sanofi-Aventis U.S. LLC

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Recall initiated
October 22, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Cool Mint Maximum Strength Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219 NDC's: 41167-0320-1 41167-0320-2 41167-0320-3 41167-0320-4 41167-0320-5 41167-0320-6 41167-0320-7

by Sanofi-Aventis U.S. LLC

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Recall initiated
October 22, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Regular Strength Zantac 150 mg Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219. NDC 05269-220-25.

by Sanofi-Aventis U.S. LLC

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Recall initiated
October 22, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Maximum Strength Zantac 150 mg Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219. NDC's 41167-0310-1 41167-0310-2 41167-0310-3 41167-0310-4 41167-0310-6 41167-0310-7 41167-0310-8

by Sanofi-Aventis U.S. LLC

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Recall initiated
October 22, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219 NDC's 41167-0300-0, 41167-0300-1, 41167-0300-3, 41167-0300-5, 41167-0300-6, 41167-0300-7, 41167-0300-8

by Sanofi-Aventis U.S. LLC

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Recall initiated
October 22, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

LETS GEL KIT Convenience Pack (To prepare 100 mL LETS GEL), Contains: LETS Powders for Gel: Lidocaine Hydrochloride - 4 g, Ephinephrine Bitartrate - 180 mg, Tetracaine Hydrochloride - 500 mg, Sodium Metabisulfite - 75 mg, SuturaGel Methlcellulose Base; RX Only, For Prescription Compounding, Fagron, Inc., 2400 Pilot Knob Rd, St. Paul, MN 55120. NDC: 51552-1539-1

by Fagron, Inc

Reason
Microbial contamination of non-sterile product.
Recall initiated
October 31, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,

by Pacira Pharmaceuticals, Inc.

Reason
Sub Potent Drug: Out of Specification (OOS)
Recall initiated
November 21, 2019
Reported by FDA
December 11, 2019
Distribution
Distributed Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Fluphenazine Decanoate Injection USP 125mg/5mL, (5 mL Multiple Dose Vial), Rx only, For IM or SC Use, Mfd in India for: AuroMedics Pharma, LLC, E. Windsor, NJ

by AuroMedics Pharma LLC

Reason
Discoloration; Hazy solution found in one vial instead of a clear solution.
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Product was distributed to major wholesalers/distributors who may have further distribute the product throughout the United States.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 550 mcg/55 mL (10 mcg/mL) in 0.9% Sodium Chloride 55 mL Syringe Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1274-50

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 2500 mcg/50 mL (50 mcg/mL) 50 mL bag, Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1436-76

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 800 mcg/200 mL (4 mcg/mL) BUPivacaine HCl 0.1667% 333.4 mg/200 mL (1.667 mg/mL) in 0.9% Sodium Chloride 200 mL in 250 mL CADD Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1436-76

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 1250 mcg/250 mL (5 mcg/mL) in 0.9% Sodium Chloride 250 mL Bag Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1444-05

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 400 mcg/200 mL (2 mcg/mL) ROPivacaine HCl 0.1% 200 mg/200 mL (1 mg/mL) in 0.9% Sodium Chloride 200 mL CADD, Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1441-76

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 2000 mcg/100 mL (20 mcg/mL) in 0.9% Sodium Chloride, 100 mL Bag, Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1094-36

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 200 mcg/100 mL (2 mcg/mL) ROPivacaine HCl 0.2% 200 mg/100 mL (2 mg/mL) in 0.9% Sodium Chloride , 100 mL bag, Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1108-36

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 2750 mcg/55 mL (50 mcg/mL) 55 mL Syringe, Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1100-50

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

fentaNYL 200 mcg/100 mL (2 mcg/mL) ROPivacaine HCl 0.2% 200 mg/100 mL (2 mg/mL) in 0.9% Sodium Chloride 100 mL CADD, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478NDC 70092-1259-75

by QuVa Pharma, Inc.

Reason
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recall initiated
November 12, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide.

View recall →

Drug Recall Ongoing Historical recordClass II

Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219. NDC's 67751-152-01 67751-152-02

by Sanofi-Aventis U.S. LLC

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Recall initiated
October 22, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219. NDC 50269-222-25.

by Sanofi-Aventis U.S. LLC

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Recall initiated
October 22, 2019
Reported by FDA
December 11, 2019
Distribution
Nationwide

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.